Annotation Detail
Information
- Associated Genes
- ALK
- Associated Variants
- ALK EML4-ALK S1206Y
- Associated Disease
- cancer
- Source Database
- CIViC Evidence
- Description
- Ba/F3 cells expressing the EML4-ALK S1206Y variant were treated with ceritinib, and survival GI50 value of 1.5 nM was obtained, which compares favorably with GI50 of 1.7 for the highly ceritinib sensitive EML4-ALK wild-type variant obtained in parallel experiments, as well as the GI50 value of 16 nM obtained for crizotinib treatment of EML4-ALK wild-type.
- Variant Origin
- somatic
- Variant Origin
- Somatic
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/1343
- Gene URL
- https://civic.genome.wustl.edu/links/genes/1
- Variant URL
- https://civic.genome.wustl.edu/links/variants/172
- Rating
- 2
- Evidence Type
- Predictive
- Disease
- Cancer
- Evidence Direction
- Supports
- Drug
- Ceritinib
- Evidence Level
- D
- Clinical Significance
- Sensitivity/Response
- Pubmed
- 24675041
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| Ceritinib | Sensitivity | true |